Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Reexamination Certificate
2011-08-16
2011-08-16
Wang, Shengjun (Department: 1627)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
C514S179000
Reexamination Certificate
active
07998947
ABSTRACT:
The subject invention pertains to the treatment of tumors and cancerous tissues and the prevention of tumorigenesis and malignant transformation through the modulation of JAK/STAT3 intracellular signaling. The subject invention concerns pharmaceutical compositions containing cucurbitacin I, or a pharmaceutically acceptable salt or analog thereof, to a patient, wherein the tumor is characterized by the constitutive activation of the JAK/STAT3 intracellular signaling pathway. The present invention further pertains to methods of moderating the JAK and/or STAT3 signaling pathways in vitro or in vivo using cucurbitacin I, or a pharmaceutically acceptable salt or analog therof. Another aspect of the present invention concerns a method for screening candidate compounds for JAK AND/or STAT3 inhibition and anti-tumor activity.
REFERENCES:
patent: 4867978 (1989-09-01), Gold
patent: 4921963 (1990-05-01), Skov et al.
patent: 5681950 (1997-10-01), Echeverri-Lopez et al.
patent: 5683698 (1997-11-01), Chavali et al.
patent: 5925356 (1999-07-01), Subbiah
patent: 5962527 (1999-10-01), Pezzuto et al.
patent: 6149912 (2000-11-01), Gubarev et al.
patent: 6200780 (2001-03-01), Chen et al.
patent: 6265160 (2001-07-01), Leonard
patent: 6531645 (2003-03-01), Sebti et al.
patent: 6914158 (2005-07-01), Webber et al.
patent: 6998394 (2006-02-01), Tomassini et al.
patent: 7108870 (2006-09-01), Sangwan et al.
patent: 2003/0018003 (2003-01-01), Sebti
patent: 2004/0138189 (2004-07-01), Sebti et al.
patent: 2005/0049299 (2005-03-01), Aggarwal
patent: 2007/0123502 (2007-05-01), Turkson et al.
patent: WO 01/97828 (2001-12-01), None
patent: WO 2005/082392 (2005-09-01), None
Fuller, RW et al. Cucurbitacins: Differential Cytotoxicity, Dereplication and First Isolation from Gonystylus Keithii. Journal of Natural Products. (1994). vol. 57, No. 10, pp. 1442-1445.
Duncan et al. Cucurbitacin E-Induced Disruption of the Actin and Vimentin Cytoskeleton in Prostate Carcinoma Cells. Biochemical Pharmacology. (1996). vol. 52, pp. 1553-1560.
Ni et al. Inhibition of Constitutively Activated Stat 3 Signaling Pathway Suppresses Growth of Prostate Cancer cells. Cancer Research. (2000). vol. 60, pp. 1225-1228.
Heim, MH. The Jak-STAT pathway: specific signal transduction from the cell membrane to the nucleus. European Journal of Clinical Investigation (1996). vol. 26, pp. 1-12.
Kupchan, S.M. Tumor Inhibitors. XXIII. The Cytotoxic Principles of Marah Oreganus H. Journal of Medicinal Chemistry. (1967). vol. 10, Issue 5. pp. 976-979.
Golub et al. Science. (1999). vol. 286, pp. 531-537.
Bowman, T. et al. “STATs in oncogenesis”Oncogene, 2000, 19:2474-2488.
Bowman, T. et al. “Signal transducers and activators of transcription: Novel targets for anticancer therapeutics”Cancer Control, 1999, 6(5):427-435.
Duncan, K.L. et al. “Cucurbitacin E-induced disruption of the actin and vimentin cytoskeleton in prostate carcinoma cells”Biochem Pharmacol, 1996, 52:1553-1560.
Duncan, M.D. and K.L. Duncan “Cucurbitacin E targets proliferating endothelia”J. Surg. Res., 1997, 69:55-60.
Konoshima, T. et al. “Inhibitory effects of cucurbitane triterpenoids on Epstein-Barr Virus activation and two-stage carcinogenesis of skin tumor. II”Biol. Pharm. Bull., 1995,18(2):284-287.
Musza, L.L. et al. “Cucurbitacins, cell adhesion inhibitors fromConobea scoparioides” J.Nat. Prod., 1994, 57:1498-1502.
Smit, H.F. et al. “Inhibition of T-lymphocyte proliferation by cucurbitacins fromPicrorhiza scrophulariaeflora” J.Nat. Prod., 2000, 63:1300-1302.
Turkson, J. and Jove, R. “STAT proteins: novel molecular targets for cancer drug discovery”Oncogene, 2000, 19:6613-6626.
Witkowski, A. et al. “Inhibition of the biosynthesis of deoxyribonucleic acid, ribonucleic acid and protein in HeLa S3 cells by cucurbitacins, glucocorticoid-like cytotoxic triterpenes”Biochem Pharmacol, 1984, 33:995-1004.
Kupchan, S. Morris et al. “Tumor Inhibitors. Active Principles of Acnistus arborescens. Isolation and Structural and Spectral Studies of Withaferin A and Withacnistin”The Journal of Organic Chemistry1969, 34, No. 12:3858-3866.
Gura, Trisha “Systems for Identifying New Drugs are Often Faulty”Science, New Series, 1997, 278 (5340):1041-1042.
Golub, T.R. et al. “Molecular classification of cancer: Class discovery and class prediction by gene expression monitoring”Science, 1999, 286:531-537.
Sun J., et al., “CucurbitacinQ: a selective STAT3 activation inhibitor with potent antitumor activity”Oncogene, 2005, 24, 3236-3245.
Birch et al. “A randomized study of etoposide and carboplatin with or without paclitaxel in the treatment of small cell lung cancer”Semin. Oncol., 1997, S12-135-S12-137, vol. 24, No. 4 Suppl., abstract only.
Sun, J. et al. “Cucurbitacin Q: a selective STAT3 activation inhibitor with potent antitumor activity”Oncogene, 2008, 27:1344.
Jove Richard
Sebti Said M.
Jean-Louis Samira
Saliwanchik Lloyd & Eisenschenk
University of South Florida
Wang Shengjun
LandOfFree
Materials and methods for treatment of cancer and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Materials and methods for treatment of cancer and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Materials and methods for treatment of cancer and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2684444